Un programme universitaire novateur contribue à un bassin de talents solide et durable pour les laboratoires nucléaires nationaux du Canada et le secteur nucléaire canadien
Un programme universitaire novateur contribue à un bassin de talents solide et durable pour les laboratoires nucléaires nationaux du Canada et le secteur nucléaire canadien
Zurich, July 29, 2025 – MetrioPharm AG, a pharmaceutical company developing drugs for inflammatory and infectious diseases, announced today that the European Medicines Agency has granted Orphan Drug Designation (ODD) to its lead compound, MP1032 for the treatment of children affected by Duchenne muscular dystrophy (DMD). This milestone follows the U.S. FDA's ODD, underscoring MP1032's potential as a first-in-class therapy that could minimize reliance on high-dose corticosteroids, which cause severe side effects like osteoporosis, growth stunting, and metabolic issues.